AGAP2 and urinary bladder cancer: We also emphasized the importance of correctly using suitable compounds and leveraging the high drug-loading properties of graphene in a precise combination of gene therapy and drug therapy to improve treatment outcomes for GBM patients.48 AGAP2-AS1, LINC01503, LINC01127, HOXC13-AS and ZMIZ1-AS1 were expressed in IMvigor210 bladder cancer, but unexpectedly, high-risk scores were associated with high survival rates.